Business Insider
My Markets Watchlist
Markets Stocks

DexCom Inc. Stock , DXCM

85.01 -0.65 -0.76%
01:11:29 PM BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Tuesday morning 06/10/2025 the DexCom Inc. share started trading at the price of $85.81. Compared to the closing price on Monday 06/09/2025 on BTT of $85.66, this is a gain of 0.18%. There are 392.11 M shares outstanding in DexCom Inc., which values the company at $27.67 B.
Is DexCom stock a Buy, Sell or Hold? DexCom stock has received a consensus rating of buy. The average rating score is and is based on 33 buy ratings, 15 hold ratings, and 0 sell ratings.
What was the 52-week low for DexCom stock? The low in the last 52 weeks of DexCom stock was 57.54. According to the current price, DexCom is 147.76% away from the 52-week low.
What was the 52-week high for DexCom stock? The high in the last 52 weeks of DexCom stock was 118.67. According to the current price, DexCom is 71.64% away from the 52-week high.
What are analysts forecasts for DexCom stock? The 48 analysts offering price forecasts for DexCom have a median target of 122.00, with a high estimate of 165.00 and a low estimate of 75.00. The median estimate represents a 69.69 difference from the last price of 85.02.

DexCom Stock Snapshot

84.99
Bid
100.00
Bid Size
85.06
Ask
25.00
Ask Size
6/10/2025
Date
1:11 PM
Time
36,945.00
Volume
85.66
Prev. Close
85.81
Open
33.62 B
Market Cap in USD
392.11 M
Number of Shares
392.11 M
Total Number of Shares
84.51
Day Low
85.96
Day High
85.01
57.54
52 Week Low
118.67
52 Week High
85.01
0.00
Dividend in USD
0.00
Dividend Yield
54.61
P/E Ratio
98.56
Free Float in %
1.42
EPS in USD
5.38
Book Value per Share in USD
2.40
Cash Flow per Share in USD

Historical Prices for DexCom

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

DexCom Analyst Data

Total Analysts: 48
Buy Ratings: 33 Neutral Ratings: 15 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 75.00 Median: 122.00 Highest: 165.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

DexCom Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
05/30/25 Goldman Sachs
Maintained Buy $104
05/22/25 Citigroup Corp.
Maintained Buy $102
05/05/25 Barclays Capital
Maintained Hold $93
05/02/25 Capital Depesche
Maintained Buy $106
05/02/25 Piper Sandler
Maintained Buy $90
05/02/25 Baird Patrick & Co
Maintained Buy $105
04/10/25 Mizuho
Maintained Buy $85
03/04/25 Citigroup Corp.
Maintained Buy $104
02/14/25 Capital Depesche
Maintained Buy $103
02/14/25 Morgan Stanley
Maintained Hold $82
07/29/24 Barclays Capital
Maintained Hold $113
07/26/24 BTIG Research
Maintained Buy $120
07/26/24 Morgan Stanley
Maintained Hold $75
07/26/24 Oppenheimer & Co. Inc.
Maintained Buy $115
07/26/24 UBS
Maintained Buy $95
07/26/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $90
07/26/24 Piper Sandler
Maintained Buy $90
07/26/24 RBC Capital Markets
Maintained Buy $145
07/26/24 Wells Fargo & Co
Maintained Buy $80
07/26/24 Capital Depesche
Maintained Buy $89
07/26/24 J.P. Morgan
Downgraded to Hold $75
07/23/24 Capital Depesche
Maintained Buy $145
07/15/24 Morgan Stanley
Maintained Hold $120
07/12/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $132
04/26/24 Raymond James Financial, Inc.
Maintained Buy $160
04/26/24 Capital Depesche
Maintained Buy $145
04/10/24 UBS
Maintained Buy $163
04/03/24 Citigroup Corp.
Maintained Buy $161
03/12/24 RBC Capital Markets
Maintained Buy $165
01/23/24 Raymond James Financial, Inc.
Maintained Buy $151
01/03/24 Raymond James Financial, Inc.
Maintained Buy $147
12/19/23 Piper Sandler
Maintained Buy $150
12/13/23 Wells Fargo & Co
Maintained Buy $136
12/04/23 Morgan Stanley
Maintained Hold $122
10/27/23 Morgan Stanley
Maintained Hold $101
10/17/23 J.P. Morgan
Maintained Buy $100
10/10/23 Stifel, Nicolaus & Co., Inc.
Maintained Buy $145
09/29/23 Morgan Stanley
Maintained Hold $98
09/15/23 Raymond James Financial, Inc.
Maintained Buy $131
09/06/23 UBS
Maintained Buy $138
08/21/23 Baird Patrick & Co
Maintained Buy $130
07/31/23 Barclays Capital
Maintained Hold $138
07/28/23 Piper Sandler
Maintained Buy $160
07/28/23 Capital Depesche
Maintained Buy $150
07/28/23 Raymond James Financial, Inc.
Maintained Buy $154
07/28/23 Baird Patrick & Co
Maintained Buy $153
07/11/23 Citigroup Corp.
Maintained Buy $150
06/26/23 BTIG Research
Maintained Buy $150

DexCom Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 4,615 5,321 6,099 7,088 7,831
Dividend 0.00 0.00 0.00 0.00 -
Dividend Yield (in %) 0.00 % 0.00 % 0.00 % 0.00 % -
EPS 2.03 2.54 3.12 3.92 4.47
P/E Ratio 42.30 33.74 27.49 21.84 19.16
EBIT 961 1,235 1,530 1,937 2,229
EBITDA 1,365 1,676 2,036 2,506 2,870
Net Profit 807 - - 1,619 1,864
Net Profit Adjusted 807 - - 1,619 1,864
Pre-Tax Profit 1,053 1,319 1,623 2,057 2,351
Pre-Tax Profit Reported 1,060 1,478 1,895 2,449 2,890
EPS (Non-GAAP) ex. SOE 2.03 2.54 3.12 3.92 4.47
EPS (GAAP) 1.95 2.54 3.19 4.02 4.49
Gross Income - - - 4,776 5,358
Cash Flow from Investing -259 -292 -374 -284 -169
Cash Flow from Operations 1,216 1,454 1,764 2,136 2,436
Cash Flow from Financing -404 -243 -240 -679 79
Cash Flow per Share 3.08 4.07 4.80 - -
Free Cash Flow 937 1,225 1,611 1,881 -
Free Cash Flow per Share 1.70 2.81 3.54 5.10 5.99
Book Value per Share 8.63 11.17 14.06 - -
Net Debt - - - -3,302 -
Research & Development Exp. - - - 868 935
Capital Expenditure 314 339 368 329 310
Selling, General & Admin. Exp. - - - 1,974 2,195
Shareholder’s Equity 2,957 4,135 5,426 7,699 9,870
Total Assets 7,147 8,306 9,767 11,416 13,772
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 22 22 24 25
Average Estimate - 0.446 USD 0.565 USD 2.026 USD 2.539 USD
Year Ago - 0.360 USD 0.341 USD 1.464 USD -
Publish Date - 7/24/2025 10/23/2025 - -
Revenue Estimates
No. of Analysts - 21 21 24 24
Average Estimate - 1,126 USD 1,169 USD 4,615 USD 5,321 USD
Year Ago - 1,004 USD 994 USD 4,033 USD -
Publish Date - 7/24/2025 10/23/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 4,033.00 3,622.30 2,909.80 2,448.50 1,926.70 1,476.00 1,031.60
Change of sales in % 11.34 24.49 18.84 27.08 30.54 43.08 43.58
Gross profit on sales 2,431.50 2,280.80 1,875.60 1,680.50 1,280.10 931.50 663.90
Gross profit on sales change in % 6.61 21.60 11.61 31.28 37.42 40.31 34.91
Operating income 600.00 597.70 391.20 265.80 299.50 142.30 -180.90
Operating income change in % 0.38 52.79 47.18 -11.25 110.47 - -443.24
Income before tax 709.00 710.40 390.80 173.90 225.00 104.20 -126.50
Income before tax change in % -0.20 81.78 124.73 -22.71 115.93 - -160.29
Income after tax 576.20 541.50 341.20 154.70 493.60 101.10 -127.10
Income after tax change in % 6.41 58.70 120.56 -68.66 388.23 - -153.19

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 4,381.90 4,195.90 3,259.90 2,612.10 2,556.20 1,512.40 1,252.70
Long-term liabilities per share 3.71 6.85 3.68 4.86 5.05 3.14 2.86
Equity 2,102.60 2,068.60 2,131.80 2,251.50 1,826.50 882.60 663.30
Equity change in % 1.64 -2.96 -5.32 23.27 106.95 33.06 58.15
Balance sheet total 6,484.50 6,264.50 5,391.70 4,863.60 4,382.70 2,395.00 1,916.00
Balance sheet total change in % 3.51 16.19 10.86 10.97 82.99 25.00 111.92

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 9.77 8.51 6.81 6.12 4.94 4.00 2.92
P/E ratio (year end quote, basic EPS) 54.61 95.29 141.89 347.41 73.03 199.73 -
P/E ratio (year end quote, diluted EPS) 54.61 95.29 141.89 347.41 73.03 199.73 -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Equity ratio in % 32.43 33.02 39.54 46.29 41.68 36.85 34.62
Debt ratio in % 67.57 66.98 60.46 53.71 58.32 63.15 65.38

DexCom Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Stern Sadie 05/26/2025 6,184.00 109,621.00 85.11 Sell No
Brown Michael Jon 05/22/2025 10,000.00 95,602.00 84.28 Sell No
Coleman Jon 05/21/2025 68,738.00 68,738.00 n/a Buy No
TOPOL ERIC 05/07/2025 2,618.00 n/a n/a Sell No
Collins Richard Alexander 05/07/2025 2,632.00 n/a n/a Sell No
ALTMAN STEVEN R 05/07/2025 2,613.00 n/a n/a Sell No
Dahut Karen M 05/07/2025 2,613.00 n/a n/a Sell No
FOLETTA MARK G 05/07/2025 2,973.00 n/a n/a Sell No
AUGUSTINOS NICHOLAS 05/07/2025 2,618.00 n/a n/a Sell No
Collins Richard Alexander 05/07/2025 5,074.00 5,074.00 n/a Buy No
ALTMAN STEVEN R 05/07/2025 2,613.00 58,630.00 n/a Buy No
Driscoll Rimma 05/07/2025 5,074.00 11,714.00 n/a Buy No
TOPOL ERIC 05/07/2025 2,618.00 380,545.00 n/a Buy No
Collins Richard Alexander 05/07/2025 2,632.00 41,942.00 n/a Buy No
ALTMAN STEVEN R 05/07/2025 5,037.00 5,037.00 n/a Buy No
GALA RENEE D 05/07/2025 5,074.00 10,794.00 n/a Buy No
Heller Bridgette P 05/07/2025 5,046.00 28,043.00 n/a Buy No
Dahut Karen M 05/07/2025 2,613.00 17,779.00 n/a Buy No
FOLETTA MARK G 05/07/2025 5,731.00 5,731.00 n/a Buy No
FOLETTA MARK G 05/07/2025 2,973.00 59,371.00 n/a Buy No
AUGUSTINOS NICHOLAS 05/07/2025 2,618.00 39,701.00 n/a Buy No
Malady Kyle 05/07/2025 5,192.00 23,334.00 n/a Buy No
AUGUSTINOS NICHOLAS 05/07/2025 5,046.00 5,046.00 n/a Buy No
Heller Bridgette P 03/16/2025 352.00 22,997.00 70.33 Sell No
Brown Michael Jon 03/11/2025 13,000.00 105,602.00 70.38 Sell No

DexCom Dividend Calendar

Date Name Dividend *yield Currency
2024 DexCom Inc. 0.00 0.00 USD
2023 DexCom Inc. 0.00 0.00 USD
2022 DexCom Inc. 0.00 0.00 USD
2021 DexCom Inc. 0.00 0.00 USD
2020 DexCom Inc. 0.00 0.00 USD
2019 DexCom Inc. 0.00 0.00 USD
2018 DexCom Inc. 0.00 0.00 USD
2017 DexCom Inc. 0.00 0.00 USD
2016 DexCom Inc. 0.00 0.00 USD
2015 DexCom Inc. 0.00 0.00 USD
2014 DexCom Inc. 0.00 0.00 USD
2013 DexCom Inc. 0.00 0.00 USD
2012 DexCom Inc. 0.00 0.00 USD
2011 DexCom Inc. 0.00 0.00 USD
2010 DexCom Inc. 0.00 0.00 USD
2009 DexCom Inc. 0.00 0.00 USD
*Yield of the Respective Date

DexCom Calendar

Event Estimate Info Date
Earnings Report 0.446 USD Q2 2025 Earnings Release 07/24/2025
Earnings Report 0.566 USD Q3 2025 Earnings Release 10/23/2025
Earnings Report 0.694 USD Q4 2025 Earnings Release 02/05/2026
Earnings Report 0.489 USD Q1 2026 Earnings Release 04/23/2026

DexCom Past Events

Event Actual EPS Info Date
Earnings Report 0.270 USD Q1 2025 Earnings Release 05/01/2025
Earnings Report 0.380 USD Q4 2024 Earnings Release 02/13/2025
Earnings Report 0.340 USD Q3 2024 Earnings Release 10/24/2024
Earnings Report 0.350 USD Q2 2024 Earnings Release 07/25/2024
Annual General Meeting 1.300 USD Annual General Meeting 05/22/2024
Earnings Report 0.360 USD Q1 2024 Earnings Release 04/25/2024
Earnings Report 0.620 USD Q4 2023 Earnings Release 02/08/2024
Earnings Report 0.290 USD Q3 2023 Earnings Release 10/26/2023
Earnings Report 0.280 USD Q2 2023 Earnings Release 07/27/2023
Annual General Meeting 0.820 USD Annual General Meeting 05/18/2023
Earnings Report 0.120 USD Q1 2023 Earnings Release 04/27/2023
Earnings Report 0.220 USD Q4 2022 Earnings Release 02/09/2023
Earnings Report 0.240 USD Q3 2022 Earnings Release 10/27/2022
Earnings Report 0.120 USD Q2 2022 Earnings Release 07/28/2022
Annual General Meeting 0.388 USD Annual General Meeting 05/19/2022
Earnings Report 0.233 USD Q1 2022 Earnings Release 04/28/2022
Earnings Report -0.050 USD Q4 2021 Earnings Release 02/10/2022

DexCom Profile

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
4
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

DexCom Management

Name Job
Kevin Ronald Sayer Chairman & Chief Executive Officer
Jon Curtis Coleman Chief Commercial Officer
Jereme M Sylvain Chief Financial Officer & Executive Vice President
Sadie M Stern Chief Human Resources Officer & Executive VP
Stacey Stewart Chief Information Officer & Senior Vice President
Michael Jon Brown Chief Legal Officer & Executive Vice President
Girish Naganathan Chief Technology Officer & Executive VP
Donald M. Abbey Executive VP-IT, Quality & Regulatory Affairs
Matt V. Dolan Executive VP-Strategy & Corporate Development
Barry J. Regan Executive Vice President-Global Operations
Paul R. Flynn Executive Vice President-Global Revenue
Leverne Marsh Executive Vice President-Marketing
Bridgette P. Heller Independent Director
Kyle J. Malady Independent Director
Nicholas Augustinos Independent Director
Richard Alexander Collins Independent Director
Rimma Driscoll Independent Director
Steven R. Altman Independent Director
Renée D. Galá Independent Director
Mark G. Foletta Lead Independent Director
Jacob S. Leach President & Chief Operating Officer
Sean Christensen Vice President-Finance & Investor Relations